scholarly journals COMBORIDITY OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE AND CARDIOVASCULAR DISEASES: GENERAL FACTORS, PATHOPHYSIOLOGICAL MECHANISMS AND CLINICAL SIGNIFICANCE

2020 ◽  
Author(s):  
Aleksey Mikhailovich Chaulin ◽  
Julia Vladimirovna Grigoryeva ◽  
Dmitriy Viktorovich Duplyakov
Keyword(s):  
Oxidative Stress ◽  
Chronic Obstructive Pulmonary Disease ◽  
Cardiovascular Diseases ◽  
Pulmonary Disease ◽  
Sedentary Lifestyle ◽  
Current Knowledge ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
High Prevalence ◽  
Common Risk Factors

Currently, the comorbidity (combination) of chronic obstructive pulmonary disease (COPD) and cardiovascular diseases (CVD) is an relevant problem for health care. This is due to the high prevalence and continued growth of these pathologies. CVD and COPD have common risk factors and mechanisms underlying their development and progression: smoking, inflammation, sedentary lifestyle, aging, oxidative stress, air pollution, and hypoxia. In this review, we summarize current knowledge relating to the prevalence and frequency of cardiovascular diseases in people with COPD and the mechanisms that underlie their coexistence. The implications for clinical practice, in particular the main problems of diagnosis and treatment of COPD/CVD comorbidity, are also discussed.

scholarly journals Cardiovascular diseases and chronic obstructive pulmonary disease: etiopathogenetic relationship and clinical signifi cance (literature review)

2020 ◽  
Vol 35 (2) ◽  
pp. 26-34
Author(s):  
A. M. Chaulin ◽  
D. V. Duplyakov
Keyword(s):  
Oxidative Stress ◽  
Risk Factors ◽  
Chronic Obstructive Pulmonary Disease ◽  
Cardiovascular Diseases ◽  
Pulmonary Disease ◽  
Sedentary Lifestyle ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
The Relationship ◽  
And Oxidative Stress

Cardiovascular diseases (CVD) and chronic obstructive pulmonary disease (COPD) often coexist. Comorbidity of CVD and COPD is a serious modern medical and social problem. This article discusses the main risk factors that are common for COPD and CVD: smoking, infl ammation, a sedentary lifestyle, aging, and oxidative stress. Pathogenetic mechanisms underlying the relationship between COPD and CVD are also discussed.

scholarly journals Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers

Kardiologiia ◽  
2019 ◽  
Vol 59 (6) ◽  
pp. 48-55 ◽  
Author(s):  
Yu. N. Belenkov ◽  
O. A. Tsvetkova ◽  
E. V. Privalova ◽  
G. V. An ◽  
I. S. Ilgisonis ◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Cardiovascular Diseases ◽  
Pulmonary Disease ◽  
Beta Blockers ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Copd Patients ◽  
Common Risk Factors ◽  
Artery Disease ◽  
Morbidity Risk

Chronic obstructive pulmonary disease (COPD) is the fourth largest cause of worldwide mortality.  Presence of comorbidities is registered in 96% of COPD patients. The most important of these are cardiovascular diseases (coronary artery disease, arterial hypertension, chronic heart failure), which contribute to COPD patients’ mortality in every third case. COPD and cardiovascular diseases have common risk factors and pathogenesis mechanisms. Cardioselective beta-blockers reduce morbidity risk and frequency of COPD exacerbation, are effective and safe in treatment of COPD patients.

scholarly journals Novel drug delivery systems targeting oxidative stress in chronic obstructive pulmonary disease: a review

2020 ◽  
Vol 18 (1) ◽  
Author(s):  
You Xu ◽  
Hongmei Liu ◽  
Lei Song
Keyword(s):  
Oxidative Stress ◽  
Chronic Obstructive Pulmonary Disease ◽  
Drug Delivery ◽  
Pulmonary Disease ◽  
Drug Delivery Systems ◽  
Current Knowledge ◽  
Delivery Systems ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease ◽  
Novel Drug

Abstract Oxidative stress is significantly involved in the pathogenesis and progression of chronic obstructive pulmonary disease (COPD). Combining antioxidant drugs or nutrients results in a noteworthy therapeutic value in animal models of COPD. However, the benefits have not been reproduced in clinical applications, this may be attributed to the limited absorption, concentration, and half-life of exogenous antioxidants. Therefore, novel drug delivery systems to combat oxidative stress in COPD are needed. This review presents a brief insight into the current knowledge on the role of oxidative stress and highlights the recent trends in novel drug delivery carriers that could aid in combating oxidative stress in COPD. The introduction of nanotechnology has enabled researchers to overcome several problems and improve the pharmacokinetics and bioavailability of drugs. Large porous microparticles, and porous nanoparticle-encapsulated microparticles are the most promising carriers for achieving effective pulmonary deposition of inhaled medication and obtaining controlled drug release. However, translating drug delivery systems for administration in pulmonary clinical settings is still in its initial phases.

Comorbidity: chronic obstructive pulmonary disease and cardiovascular diseases

2020 ◽  
Vol 18 (1) ◽  
pp. 26-31 ◽  
Author(s):  
A. M. CHAULIN ◽  
◽  
Yu. V. GRIGORYEVA ◽  
D. V. DUPLYAKOV ◽  
◽  
...  
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Cardiovascular Diseases ◽  
Pulmonary Disease ◽  
Chronic Obstructive ◽  
Obstructive Pulmonary Disease

Screening of High-risk Patients for Chronic Obstructive Pulmonary Disease in Primary Care: A Narrative Review (Preprint)

2020 ◽  
Author(s):  
Ponrathi Athilingam ◽  
Andrew Bugajski ◽  
Usha Menon
Keyword(s):  
Chronic Obstructive Pulmonary Disease ◽  
Lung Function ◽  
Pulmonary Disease ◽  
Current Knowledge ◽  
Screening Tools ◽  
Chronic Obstructive ◽  
Early Screening ◽  
Obstructive Pulmonary Disease ◽  
Impaired Lung Function ◽  
Risk Patients

UNSTRUCTURED Chronic obstructive pulmonary disease (COPD) predominantly affects older adults, and claimed 3 million lives in 2016, making it the third leading cause of death worldwide. Over 35 million Americans aged 40 or older have lung function consistent with diagnosable COPD. COPD and cardiovascular disease (CVD) have a bidirectional relationship, in that one is a risk factor for developing the other. National and international consortiums recommend early screening of adults at risk of COPD, such as those with CVD. Recommended screening strategies include screening tools to assess symptoms, medical history, and handheld spirometry. Handheld spirometry has high diagnostic accuracy and if impaired lung function is indicated, these patients are referred for pulmonary function testing (PFT), the diagnostic gold standard for COPD. However, there is no clinical consensus for pulmonary screening in people with CVD. Current knowledge relating to the prevalence and incidence of CVD in people with COPD and the mechanisms that underlie their coexistence is key in combating the global burden of COPD.

Oxidized low-density lipoproteins and its connection with dyslipidemia, inflammatory markers, and oxidative stress in patients with occupational chronic obstructive pulmonary disease

2021 ◽  
Vol 31 (4) ◽  
pp. 456-462
Author(s):  
I. A. Umnyagina ◽  
L. A. Strakhova ◽  
T. V. Blinova ◽  
V. V. Troshin ◽  
V. D. Fedotov
Keyword(s):  
Oxidative Stress ◽  
Chronic Obstructive Pulmonary Disease ◽  
Pulmonary Disease ◽  
Comparison Group ◽  
Serum Levels ◽  
Low Density Lipoproteins ◽  
Chronic Obstructive ◽  
Low Density ◽  
Obstructive Pulmonary Disease ◽  
Occupational Copd

The role of low-density oxidized lipoproteins (OxLDL) in the pathogenesis of occupational chronic obstructive pulmonary disease (COPD) is not understood well enough.The study aims to determine the serum levels of oxidized low-density lipoproteins and their relationship with lipid profile, the level of oxidative stress and level C-reactive protein in patients with occupational chronic obstructive pulmonary disease.Methods. 116 patients diagnosed with occupational COPD and 25 patients with no respiratory diseases (comparison group) were examined. Serum levels of OxLDL was determined by solid phase enzyme-linked immunosorbent assay (ELISA) using the commercial reagent kit MDA-oxLDL from Biomedica Gruppe, Austria.Results. Circulating OxLDL was detected in serum in a significant proportion of patients with stable occupational COPD. In most of the patients, the concentration of OxLDL was within the values observed in the comparison group or exceeded them by no more than two times. In the minority of patients with occupational COPD (16.5%), the concentration of OxLDL was high and 4 – 10 times higher than its average value in the comparison group. It can be assumed that the revealed differences in the concentration of OxLDL are due to the different degree and intensity of oxidation of low-density lipoproteins. The relationships between OxLDL and lipid metabolism, oxidative stress (OS), the antioxidant capacity of serum (AOS), and serum levels of C-reactive protein were described.Conclusion. Serum OxLDL levels in patients with occupational COPD, the relationship between OxLDL and lipid metabolism, oxidative stress, and inflammation will provide an expanded view of the pathogenetic aspects of occupational COPD.

Sign in / Sign up

Export Citation Format

Share Document